N/A N=43 Electrical Stimulation and Eccentric Exercise for Anterior Cruciate Ligament (ACL) Injury
Anterior Cruciate Ligament Injury
Primary: Quadriceps Strength — 2.1; 2.1; 2.8; 2.9 Nm/kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=233 Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®
Ocular Hypertension · Open Angle Glaucoma
Primary: Mean Diurnal Intraocular Pressure (IOP) at Week 6 — 17.44; 20.34 mmHg
N/A N=15 DAILIES TOTAL1® Lubricity Post Wear
Refractive Error
Primary: Average Coefficient of Friction (CF) at 16 Hours Compared to Unworn — 0.0394; 0.0396 unitless
Phase 2 N=43 Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
Esophageal Cancer · Gastric Cancer · Neoplasm Metastasis
Primary: Overall Response Rate — 0.029 proportion of paticipants
Phase 2 N=112 Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
Non-Small Cell Lung Cancer
Primary: Disease-free Survival — NA; 55.1 months
Phase 2 N=404 A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
Lower Urinary Tract Symptoms (LUTS)
Primary: Mean Change in International Prostate Symptom Score (IPSS) — -4.46; -5.65; -6.11; -5.88 percentage change from baseline — p=0.0911
Phase 2 N=289 Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)
Metastatic Colorectal Cancer
Primary: Percentage of Subjects With Best Overall Confirmed Response Rate (BORR) — 54.5; 61.2 Percentage of subjects
Phase 3 N=148 DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
Open Angle Glaucoma or Ocular Hypertension
Primary: Change From Baseline in IOP (Intraocular Pressure) at End of Study — -1.8 mmHg
Phase 3 N=489 DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%
Open Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Diurnal IOP(Intraocular Pressure) at End of Study — -2.6; -0.9; -2.2 mmHg — p=< 0.001
Phase 2 N=72 A Phase II Trial of MB-6 Plus FOLFOX4 for Metastatic Colorectal Cancer (FDA IND 103675)
Colorectal Cancer
Primary: The Primary Efficacy Endpoint of This Study is the Best Overall Response (Complete Response + Partial Response) — 61.76; 68.42 percentage of Best overall Response
Phase 2 N=125 Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Maximum Tolerated Dose of Vorinostat, Defined as the Dose at Which Fewer Than One-third of Patients Experience DLTs, Graded According to NCI CTCAE (Common Toxicity…
Phase 2 N=50 ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
Alzheimer's Disease
Primary: Treatment Emergent Adverse Events (TEAEs) — 21; 23 participants
Phase 2 N=30 Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.
Attention Deficit Disorder With Hyperactivity
Primary: RAAPP: Rating of Aggression Against People and/or Property Scale — 4.3; 3.2; 2.0 units on a scale — p=<0.05
Phase 3 N=33 Vitamin C for Prophylaxis of Post-operative Atrial Fibrillation in On-pump Cardiac Surgery Procedures
Atrial Fibrillation
Primary: Incidence of Postoperative Atrial Fibrillation — 5; 4; 5 participants
Phase 3 N=517 Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
Anemia
Primary: Incidence of Treatment-emergent Serious Adverse Events (SAE's) — 11; 36 participants